This Post Is Recently Updated on Dec 16, 2023 @ 23:40 pm by TBB Desk
Detection and Spread
- China’s Detection: On December 15, 2023, China detected seven infections of the COVID subvariant JN.1, as reported by the national disease control and prevention administration. The prevalence of JN.1 in China is currently very low, but there’s uncertainty about whether it could become the dominant strain due to factors like imported cases.
- First Detection in India: The COVID subvariant JN.1 was first detected in Kerala, India, on December 13, 2023. This discovery triggered concerns about its potential impact on rising COVID-19 cases in the region. The Indian SARS-CoV-2 Genomics Consortium (INSACOG) has confirmed the presence of JN.1 in Kerala, which is currently experiencing an increase in COVID-19 cases.
Characteristics of JN.1
- Descent and Mutation: JN.1, also known as BA.2.86.1.1 or Pirola, is a recent variant of SARS-CoV-2 descended from the BA.2.86 lineage. It contains a hallmark mutation L455S in the spike protein.
- First Detected in the U.S.: JN.1 was initially detected in the United States in September 2023 and, as of early December, is estimated to account for 15–29% of COVID-19 cases there.
- WHO’s Warning: The World Health Organization has issued a warning about JN.1 due to its over 40 mutations and the concern that existing vaccine-derived immunity might be less effective against it.
Symptoms and Severity
- Symptoms: The symptoms of JN.1 include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, and sore throat.
- Concerns Over Severity: While the full severity profile of JN.1 is not yet clear, there is concern among health experts about its potential to disrupt holiday plans and gatherings due to its transmissibility.
Global Impact
- Spread to Other Countries: JN.1 has spread to several countries. It was first detected in the U.S. in September 2023 and has since been found in 11 other countries.
- Rising Global Concern: The emergence and spread of JN.1 have led to increased global concern, particularly with its rising proportion among circulating COVID-19 variants.
The global impact of JN.1, including its transmissibility and severity, continues to be closely monitored.
